Newly identified method of gene regulation challenges accepted science, researchers say – Phys.Org

June 15, 2017

Researchers at the Stanford University School of Medicine have discovered an unexpected layer of the regulation of gene expression. The finding will likely disrupt scientists' understanding of how cells regulate their genes to develop, communicate and carry out specific tasks throughout the body.

The researchers found that cellular workhorses called ribosomes, which are responsible for transforming genes encoded in RNA into proteins, display a never-before-imagined variety in their composition that significantly affects their function. In particular, the protein components of a ribosome serve to tune the tiny machine so that it specializes in the translation of genes in related cellular pathways. One type of ribosome, for example, prefers to translate genes involved in cellular differentiation, while another specializes in genes that carry out essential metabolic duties.

The discovery is shocking because researchers have believed for decades that ribosomes functioned like tiny automatons, showing no preference as they translated any and all nearby RNA molecules into proteins. Now it appears that broad variation in protein production could be sparked not by changes in the expression levels of thousands of individual genes, but instead by small tweaks to ribosomal proteins.

'Broad implications'

"This discovery was completely unexpected," said Maria Barna, PhD, assistant professor of developmental biology and of genetics. "These findings will likely change the dogma for how the genetic code is translated. Until now, each of the 1 to10 million ribosomes within a cell has been thought to be identical and interchangeable. Now we're uncovering a new layer of control to gene expression that will have broad implications for basic science and human disease."

Barna is the senior author of the study, which will be published online June 15 in Molecular Cell. Postdoctoral scholars Zhen Shi, PhD, and Kotaro Fujii, PhD, share lead authorship. Barna is a New York Stem Cell Robertson Investigator and is also a member of Stanford's Bio-X and Child Health Research Institute.

The work builds upon a previous study from Barna's laboratory that was published June 1 in Cell. The lead author of that study was postdoctoral scholar Deniz Simsek, PhD. It showed that ribosomes also differ in the types of proteins they accumulate on their outer shells. It also identified more than 400 ribosome-associated proteins, called RAPs, and showed that they can affect ribosomal function.

Every biology student learns the basics of how the genetic code is used to govern cellular life. In broad strokes, the DNA in the nucleus carries the building instructions for about 20,000 genes. Genes are chosen for expression by proteins that land on the DNA and "transcribe" the DNA sequence into short pieces of mobile, or messenger, RNA that can leave the nucleus. Once in the cell's cytoplasm, the RNA binds to ribosomes to be translated into strings of amino acids known as proteins.

Every living cell has up to 10 million ribosomes floating in its cellular soup. These tiny engines are themselves complex structures that contain up to 80 individual core proteins and four RNA molecules. Each ribosome has two main subunits: one that binds to and "reads" the RNA molecule to be translated, and another that assembles the protein based on the RNA blueprint. As shown for the first time in the Cell study, ribosomes also collect associated proteins called RAPs that decorate their outer shell like Christmas tree ornaments.

'Hints of a more complex scenario'

"Until recently, ribosomes have been thought to take an important but backstage role in the cell, just taking in and blindly translating the genetic code," said Barna. "But in the past couple of years there have been some intriguing hints of a more complex scenario. Some human genetic diseases caused by mutations in ribosomal proteins affect only specific organs or tissues, for example. This has been very perplexing. We wanted to revisit the textbook notion that all ribosomes are the same."

In 2011, members of Barna's lab showed that one core ribosomal protein called RPL38/eL38 is necessary for the appropriate patterning of the mammalian body plan during development; mice with a mutation in this protein developed skeletal defects such as extra ribs, facial clefts and abnormally short, malformed tails.

Shi and Fujii used a quantitative proteomics technology called selected reaction monitoring to precisely calculate the quantities, or stoichiometry, of each of several ribosomal proteins isolated from ribosomes within mouse embryonic stem cells. Their calculations showed that not all the ribosomal proteins were always present in the same amount. In other words, the ribosomes differed from one another in their compositions.

"We realized for the first time that, in terms of the exact stoichiometry of these proteins, there are significant differences among individual ribosomes," said Barna. "But what does this mean when it comes to thinking about fundamental aspects of a cell, how it functions?"

To find out, the researchers tagged the different ribosomal proteins and used them to isolate RNA molecules in the act of being translated by the ribosome. The results were unlike what they could have ever imagined.

"We found that, if you compare two populations of ribosomes, they exhibit a preference for translating certain types of genes," said Shi. "One prefers to translate genes associated with cell metabolism; another is more likely to be translating genes that make proteins necessary for embryonic development. We found entire biological pathways represented by the translational preferences of specific ribosomes. It's like the ribosomes have some kind of ingrained knowledge as to what genes they prefer to translate into proteins."

The findings dovetail with those of the Cell paper. That paper "showed that there is more to ribosomes than the 80 core proteins," said Simsek. "We identified hundreds of RAPs as components of the cell cycle, energy metabolism, and cell signaling. We believe these RAPs may allow the ribosomes to participate more dynamically in these intricate cellular functions."

"Barna and her team have taken a big step toward understanding how ribosomes control protein synthesis by looking at unperturbed stem cells form mammals," said Jamie Cate, PhD, professor of molecular and cell biology and of chemistry at the University of California-Berkeley. "They found 'built-in' regulators of translation for a subset of important mRNAs and are sure to find more in other cells. It is an important advance in the field." Cate was not involved in the research.

Freeing cells from micromanaging gene expression

The fact that ribosomes can differ among their core protein components as well as among their associated proteins, the RAPs, and that these differences can significantly affect ribosomal function, highlights a way that a cell could transform its protein landscape by simply modifying ribosomes so that they prefer to translate one type of genesay, those involved in metabolismover others. This possibility would free the cell from having to micromanage the expression levels of hundreds or thousands of genes involved in individual pathways. In this scenario, many more messenger RNAs could be available than get translated into proteins, simply based on what the majority of ribosomes prefer, and this preference could be tuned by a change in expression of just a few ribosomal proteins.

Barna and her colleagues are now planning to test whether the prevalence of certain types of ribosomes shift during major cellular changes, such as when a cell enters the cell cycle after resting, or when a stem cell begins to differentiate into a more specialized type of cell. They'd also like to learn more about how the ribosomes are able to discriminate between classes of genes.

Although the findings of the two papers introduce a new concept of genetic regulation within the cell, they make a kind of sense, the researchers said.

"About 60 percent of a cell's energy is spent making and maintaining ribosomes," said Barna. "The idea that they play no role in the regulation of genetic expression is, in retrospect, a bit silly."

Explore further: In creation of cellular protein factories, less is sometimes more

Ribosomes are the cellular machines that make proteins, the molecules that carry out the majority of life's functions. To make ribosomes, cells need to make an abundance of amino acids (the raw material of proteins) and adenosine ...

The ability to dispose of proteins that are either aberrant or (in the worst case) toxic is fundamental to a cell's survival. Researchers from Charit - Universittsmedizin Berlin have been able to demonstrate the manner ...

Researchers at the Center of Genomic Integrity, within the Institute for Basic Science (IBS), have found out an unexpected role for a protein involved in the DNA repair mechanism. The protein SHPRH not only helps to fix mistakes ...

A research team at the University of Basel's Biozentrum has investigated the expression of ribosomal proteins in a wide range of human tissues including tumors and discovered a cancer type specific signature. As the researchers ...

Nikolai Slavov, a new assistant professor in the Department of Bioengineering, wasn't looking to upend conventional wisdom when he set out to measure protein levels in ribosomes, the particles in cells that synthesize all ...

Biologists at UC San Diego have found the "missing link" in the chemical system that enables animal cells to produce ribosomesthe thousands of protein "factories" contained within each cell that manufacture all of the ...

Scientists have developed a new technique for investigating the effects of gene deletion at later stages in the life cycle of a parasite that causes malaria in rodents, according to a new study in PLOS Pathogens. The novel ...

Scientists from Rutgers University-New Brunswick, the biotechnology company NAICONS Srl., and elsewhere have discovered a new antibiotic effective against drug-resistant bacteria: pseudouridimycin. The new antibiotic is produced ...

The drill holes left in fossil shells by hunters such as snails and slugs show marine predators have grown steadily bigger and more powerful over time but stuck to picking off small prey, rather than using their added heft ...

Almost all life on Earth is based on DNA being copied, or replicated. Now for the first time scientists have been able to watch the replication of a single DNA molecule, with some surprising findings. For one thing, there's ...

Researchers have identified properties in DNA's protective structure that could transform the way scientists think about the human genome.

James Cook University scientists have found evidence that even distantly related Australian fish species have evolved to look and act like each other, which confirms a central tenet of evolutionary theory.

Adjust slider to filter visible comments by rank

Display comments: newest first

Again we're shocked to discover that the higher energy environment our solar system experiences, the greater the tightening and finite organizing we see at the cellular level. What will we find only to lose it as our system passes out of higher energy is astonishing. Looking thru this lens of higher energy in past cycles reforms myths into potential truths.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:

Newly identified method of gene regulation challenges accepted science, researchers say - Phys.Org

DC Health Link – Welcome to DC’s Health Insurance Marketplace

On May 4, 2017 the U.S. House of Representatives passed a bill seeking to repeal and replace the Affordable Care Act (ACA). The debate is now in the U.S. Senate. The Affordable Care Act (ACA), at this time, remains the law of the land with all of its consumer protections for people with pre-existing conditions, women, and small businesses. DC Health Link is established in District law, locally managed and controlled, financially sound and going strong. Legislative action on May 4 doesnt impact your ability to enroll in affordable quality health insurance for 2017. You may also be eligible for premium reductions. DC Health Link has 20 private health insurance options to choose from for residents and their families from CareFirst and Kaiser Permanente. For 2017 small businesses have 151 health plan options from Aetna, CareFirst, Kaiser and United. Individuals and families can enroll if they qualify for a special enrollment due to a change in their life like getting married. Small businesses can sign up throughout the year. Residents can apply for Medicaid throughout the year.

Visit link:

DC Health Link - Welcome to DC's Health Insurance Marketplace

The Senate Health Care Bill Could Hurt You Even If You Get Insurance Through Work, Report Says – Money Magazine

At least 20 million Americans with employer-provided health insurance could find themselves one devastating accident or diagnosis away from financial ruin if the Senate health care bill is passed as expected, according to a report released Thursday by the Center for American Progress.

Lawmakers have been working behind closed doors on their American Care Act (ACA) replacement bill, whose primary focus is reshaping the individual insurance market and rolling back the ACAs expansion of Medicaid. Yet the bill may also include a provision that would weaken protections for millions of Americans with employer-sponsored health coverage, Axios reports.

Senators havent released a draft of their legislation, and media reports have said they dont intend to ahead of a vote that could happen before Congress breaks for July 4. The Center for American Progress assumed that the bill would include a waiver provision that could weaken patient protections and used survey and census data to estimate the number of workers and dependents in large company plans who would be affected.

The waiver was also included in the House version of the health care bill, the American Health Care Act, which passed on May 4.

This provision would allow employers to bring back annual and lifetime caps on health coverage. In 2009, before the ACA, 59% of workers with employer-provided health insurance were in a plan with a lifetime limit on how much the plan would cover. That cap could be set as low as $1 million, which wouldnt be hard for certain patients to hit. For example, a baby who spent months in the neonatal intensive care unit or someone who was born with hemophilia, developed an aggressive form of cancer, or got paralyzed in a car accident would all easily reach that sum.

Once a person hit his lifetime cap, the health plan would stop paying his expenses. Someone who hit his annual cap would have to wait until the following year for coverage. To a lot of people, it probably came as a surprise, says Emily Gee, a health economist at the left-leaning Center for American Progress and co-author of the report.

The Senate bill could expose workers to these caps by allowing states to apply for a waiver to define their own list of essential health benefits. The Affordable Care Act required most plans to include a robust list of 10 essential benefits, including prescription drug coverage, mental health and maternity care. The law banned annual and lifetime limits for essential health benefits, which in effect meant that most care wasnt subject to any caps.

But if states could pick and choose their essential health benefits, then employers could do the same, bringing back caps for any care that doesnt fall under their new definition of "essential." Individual and small group (generally, under 50 workers) plans in a particular state would be bound by their local regulationsso if their state mandated a full slate of essential health benefits, then they wouldnt have the option of choosing a health plan that excluded one.

By contrast, regulations allow large employers to base their benefit structure on any given states. Since essential health benefits are standard under the Affordable Care Act, this ability isnt currently that meaningful. However, if variations in essential health benefits become the norm, then employers that want to cut health costs could gravitate toward the state that offers them the most flexibility to do so.

To be sure, not all large employers will choose to set caps. Plenty of companies see comprehensive health insurance as a way to attract and keep talented employees, says Zack Pace, senior vice president of CBIZ, a benefits consulting firm. But the relentlessly rising cost of medical care and prescription drugs means that some firms may have no choice but to limit their workers coverage, Gee says.

The Center for American Progress based its estimates on a survey by Willis Towers Watson in which 20% of large employers said they would impost annual limits and 15% would impose lifetime limits if the ACA protections were repealed. Authors then used U.S. Census data to estimate the number of large-company workers and their dependents who would be affected: nearly 27 million would be subject to annual limits, and about 20 million would be subject to lifetime limits.

This worries advocates for people with pre-existing conditions. Imagine being the individual in active cancer treatment, says Anna Howard, principal in policy development at the American Cancer Society Cancer Action Network, and being told that, in effect, were not going to be paying for the products and services that are keeping you alive.

Excerpt from:

The Senate Health Care Bill Could Hurt You Even If You Get Insurance Through Work, Report Says - Money Magazine

Republicans’ ‘Mean’ Health Care Plan: The Real Cost of Trump’s AHCA Is Jobs, Study Finds – Newsweek

The Republican-controlled U.S. Senate has received constant waves of criticism over its secret tinkering with the controversial and widely panned American Healthcare Act (AHCA)even from President Donald Trump, who reportedly said it was mean and asked that it be more generous.

Trumps characterization of the bill, which passed the House of Representatives last month, could very well be correct, and may even affect one of his top campaign promises: boosting the economy and jobs.

A study examining how each state could be affected if it passes the Senate and is written into law, published Wednesday by The Commonwealth Fund,found that by 2026 nearly one million jobs could be lost, state gross domestic product could shrink by $93 billion and businesses could suffer a $148 billion bite.

Daily Emails and Alerts- Get the best of Newsweek delivered to your inbox

When the House passed the bill on May 24, critics focused in particular on the Congressional Budget Offices estimate that 23 million Americans would be uninsured by 2026 and Medicaidwould see $880 billion in cuts during the same eight years.

But the new study appears to be focusing directly on the presidents main concernthe economyone of the few places hes claimed success after five months in office.

Should the bill be passed this year and enacted in 2018, there would be initial job growththat would gradually taper off. The bill ultimately would result in the loss of jobs in as many as 10 states, according to the study.

Initially, the repeal of Obamacare would raise the federal deficit following a tax cut, and then lead to the creation of 864,000 jobs by 2018. But due to the rising costs of health care, coupled with the bills tax cuts, over time more sectors of the economy would be affected, and eventually 924,000 jobs would be lost.

Combined, tax repeal and coverage-related changes lead to initial economic and employment growth but eventual losses, the study reads.

Coverage and spending-related policies are directly related to funding for health services (e.g., Medicaid, premium tax credits, high-risk pools). The reductions directly affect the health sectorhospitals, doctors offices or pharmaciesbut then flow out to other sectors.

Thus, about two-fifths of jobs lost due to coverage policies are in the health sector, while three-fifths are in other sectors. Tax changes affect consumption broadly, spreading effects over most job sectors, the study said.

If the current version of the bill passes, job losses could significantly hit 10 states, some of which went with Trump in the Electoral College last year. Florida, Pennsylvania and New York would be affected the worst, with upwardof 80,000 jobs or more lost, while Michigan could dip by 51,000, and New Jersey, Illinois, Ohio and North Carolina by more than 40,000 each.

It also appears the entire country could have serious problems with the AHCA. ANew York Times composite of eight national polls found that on average, only 29 percent of Americans support the bill and not a single state is in favor of its passage.

Link:

Republicans' 'Mean' Health Care Plan: The Real Cost of Trump's AHCA Is Jobs, Study Finds - Newsweek

Legionella Poses Risk for Patients in Health Care Facilities – AAFP News

The CDC released a Morbidity and Mortality Weekly Report (MMWR)(www.cdc.gov) and an accompanying Vital Signs report on June 6 that analyzed the prevalence of Legionnaires' disease in the U.S. health care system and found that 76 percent of facilities studied reported health care-associated cases of the disease.

Seventy-two health care facilities in 16 of the 21 U.S. jurisdictions the CDC studied reported definite health care-related cases of Legionnaires' disease, which is known to kill one-quarter of patients who are infected.

Legionnaires' disease is a severe pneumonia typically acquired through inhalation of aerosolized water containing Legionella bacteria. Legionella can grow in the complex water systems that supply many buildings, including health care facilities, when those systems are not well managed. Thus, effective water management programs could prevent the growth of Legionella in these building water systems.

Most healthy patients who are exposed to Legionella don't develop Legionnaires' disease. Some patients, however, are at increased risk for the disease, including those 50 or older and those who have certain risk factors, such as being a current or former smoker or having a chronic disease or weakened immune system.

Legionnaires' disease in hospitals is widespread, deadly and preventable," said CDC Acting Director Anne Schuchat, M.D., in a June 6 news release.(www.cdc.gov) "These data are especially important for health care facility leaders, doctors and facility managers because it reminds them to think about the risks of Legionella in their facility and to take action.

"Controlling these bacteria in water systems can be challenging, but it is essential to protect patients."

All 50 states, two large U.S. metropolitan areas and five territories report basic demographic information to the CDC's National Notifiable Diseases Surveillance System (NNDSS) for all cases of legionellosis, which manifests as one of two distinct clinical presentations: Pontiac fever (a mild influenza-like illness) and Legionnaires' disease. NNDSS makes no distinction between the two presentations.

In 2015, a total of 6,079 cases of legionellosis were reported to NNDSS, although the CDC noted that this estimate may be low due to underdiagnosis. The Supplemental Legionnaires' Disease Surveillance System (SLDSS) receives additional epidemiologic information, including whether patients were exposed to health care facilities, and distinguishes Legionnaires' disease from Pontiac fever, but reporting to SLDSS is less widespread.

The MMWR analysis aimed to define which Legionnaires' cases were associated specifically with health care facilities using data from the 21 U.S. jurisdictions. Definite health care-associated disease was defined as including hospitalization or long-term care facility residence for 10 days preceding symptom onset; possible health care-associated disease was defined as including any exposure to a health care facility for a portion of the 10 days preceding symptom onset. All other cases were considered unrelated to health care.

The MMWR analysis aimed to define which Legionnaires' cases were associated specifically with health care facilities using data from the 21 U.S. jurisdictions. Definite health care-associated disease was defined as including hospitalization or long-term care facility residence for 10 days preceding symptom onset; possible health care-associated disease was defined as including any exposure to a health care facility for a portion of the 10 days preceding symptom onset. All other cases were considered unrelated to health care.

Of the more than 6,000 confirmed legionellosis cases reported to NNDSS in 2015, 3,516 (58 percent) were also reported to SLDSS, including 3,459 Legionnaires' disease cases. Of those Legionnaires' disease cases, 2,809 (81 percent) were reported by the 21 jurisdictions included in the MMWR analysis, including 553 (20 percent) that were health care-associated (either definite or possible).

Of the 85 Legionnaires' disease cases that were determined to be definitely health care-associated, 80 percent were associated with long-term care facilities, 18 percent with hospitals and 2 percent with both.

Definite health care-associated Legionnaires' disease cases were reported in 72 facilities -- 15 hospitals and 57 long-term care facilities -- and included one to six cases per facility. Almost 90 percent of these definite cases occurred in patients 60 or older.

Of the 468 possible health care-associated cases, 49 percent were thought to be associated with hospitals, 26 percent with clinics, 13 percent with long-term care facilities, 3 percent with other settings such as outpatient laboratories, and 9 percent with more than one setting.

The MMWR report's authors said preventing the first case of Legionnaires' disease from arising in any health care facility should be the goal, and that is best achieved by establishing and maintaining an effective water management program. To this end, the CDC and its partners have created a best practices guide(www.cdc.gov) for these facilities to use.

In general, the CDC said the principles of effective water management include maintaining water temperatures that are not conducive to Legionella growth; preventing water stagnation; ensuring adequate disinfection; and maintaining equipment to prevent scale, corrosion and biofilm growth, which provide a habitat and nutrients for Legionella.

"Safe water at a health care facility might not be on a physician's mind, but it's an essential element of health care quality," said Nancy Messonnier, M.D., director of the CDC's National Center for Immunization and Respiratory Diseases, in the agency's release. "Having a water management program that focuses on keeping facility water safe can help prevent Legionnaires' disease."

In related news, CMS released a survey and certification memo(www.cms.gov) on June 2 that requires health care facilities to develop and adhere to policies and procedures to reduce the risk of disseminating Legionella and other waterborne pathogens.

According to the CDC, health care professionals play a critical role in preventing and responding to Legionnaires' disease by rapidly identifying and reporting cases.

Unfortunately, Legionnaires' disease is clinically indistinguishable from other causes of pneumonia. But failing to diagnose a health care-associated case could result in a missed opportunity to prevent subsequent cases.

Therefore, "Legionella should be considered as a cause of health care-associated pneumonia, especially for groups at increased risk, when other facility-related cases have been identified, or when changes in water parameters might lead to increased risk for Legionnaires' disease," the MMWR report advised.

The preferred diagnostic procedure for Legionnaires' disease is to concurrently obtain a lower respiratory sputum sample for culture and perform a Legionella urinary antigen test.

The CDC said ideally, sputum should be obtained before antibiotics are administered and shouldn't be rejected based on specimen quality (e.g., lack of polymorphonuclear leukocytes or contamination with other bacteria), because sputa produced by patients with Legionnaires' disease might not be purulent, and contaminating bacteria will not negatively affect isolation of Legionella on selective media.

"This report demonstrates that Legionnaires' disease continues to result from exposures to health care facility water systems," said the MMWR report. "The high case fatality rate of health care-associated Legionnaires' disease underscores the need for effective prevention and response programs.

"Implementation and maintenance of water management programs, combined with rapid case identification and investigation, could reduce the number of health care-associated Legionnaires' disease cases."

More From AAFP American Family Physician: Recreational Waterborne Illnesses: Recognition, Treatment, and Prevention

See more here:

Legionella Poses Risk for Patients in Health Care Facilities - AAFP News

Oregon House advances $670M health care provider tax – KATU

Photo courtesy MGN Online

SALEM, Ore. (AP) A $670 million health care tax package designed to help sustain Medicaid services for the next two years and avoid the shuttering of a newly-built psychiatric hospital passed the Oregon House Thursday.

The 36-23 decision vote exceeded the constitutionally-required supermajority by just one vote.

House Bill 2391 is among the most high-profile pieces of legislation in Salem this year. Without it, lawmakers would have less than a month to solve a large chunk of the state's upcoming $1.4 billion shortfall, a psychiatric hospital in Junction City, Ore. with 100 beds and 400 workers would be on the chopping block and more than 350,000 low-income Oregon residents could lose health insurance under the federal Medicaid expansion almost immediately.

The package is among Gov. Kate Brown's top priorities she wants lawmakers to get done before the required July 10 adjournment. In a briefing with the state capitol press Wednesday, Brown noted she'd continue to fight the GOP minority's efforts in Congress to derail the Medicaid expansion and repeal President Barrack Obama's legacy legislation, the Affordable Care Act.

"The conversation, at least from what I've been able to read and in my conversations most recently with Sen. (Jeff) Merkley, is that the proposal will likely starting kicking people off after the 2020 elections," Brown said. "I find that appalling that we would keep people on for a year or two to get past the 2018 election cycle and then devastate 23 million Americans."

Passage of the so-called "provider" tax is also essential for the Oregon Health Authority's nearly $20 billion budget, proposed as a companion bill, for the 2017-19 biennium. House lawmakers approved the OHA budget, House Bill 5026, immediately following the provider tax, which squeaked by on a narrow three-fifths vote after Republican Rep. Sal Esquivel broke with his party to help majority Democrats advance the bill the next stage.

Both health care bills now head for final approval to the state Senate. The provider tax has broader support among Republicans in the Senate than it did in the House, so it's expected to clinch supermajority support more easily.

The package includes raising an existing tax on hospitals' net patient revenue 4 percent on small, rural hospitals and 6 percent on large hospitals and imposes a new 1.5 percent tax on health plans provided by some insurers as well as coordinated-care organizations that facilitate the state's Medicaid program, called the Oregon Health Plan.

The proposal has been several months in the making among Democrats, Republicans and key health care industry players, who worked in good faith toward the common goal of ensuring that billions of federal Medicaid matching-dollars, which begin tapering off next year, continue flowing into Oregon's local economy.

But negotiations were ongoing up until hours before the vote, with House Republicans opposing the premium tax as being too high.

"The inclusion of a tax on insurance premiums will result in higher health care costs for small businesses, college students and everyone in between," said Republican Rep. Cedric Hayden, who played a key role in negotiating the provider tax package. "It's disappointing that bipartisan alternatives were not given the consideration they deserved by the majority party."

See the original post:

Oregon House advances $670M health care provider tax - KATU

Apple reveals plans to put health records on the iPhone – Healthcare IT News

Apple has been in talks with hospitals and other healthcare organizations to explore the possibility of bringing health records together via iPhones, media outlets reported.

The effort to make all personal health information available via its devices would be a first for Apple, which until now has focused it healthcare work on fitness and wellness with its Apple HealthKit. Apple has been typically mum on the developments and CNBC, which first reported Apples latest intentions for healthcare, said the works has thus far been secretive.

[Also:Will Apple buy athenahealth? Jonathan Bush calls rumor baseless]

Unnamed sources told CNBC Apple is looking at startups in the cloud-hosting space to give it a foothold in healthcare.

The company has already acquired personal health data startup Gliimpse, which has a secure platform for consumers to manage and share their own medical records.

The entrepreneur Anil Sethi, who built Gliimpse and sold it to Apple three years later, is now working at Apple. His title, according to his LinkedIn page, is Director, Apple Health.

More recently, Apple recruited Sumbul Desai, MD, from Stanford, where she has been involved in several successful digital projects. Apple executives have not released what role Desai will play, whether she might join the team working on ResearchKit, HealthKit and CareKit, or work on another project altogether.

Also, Apple insiders reportedly talked with people at The Argonaut Project, which is promoting the adoption of open standards for health information, and to "The Carin Alliance," an organization that advocates for giving patients a central role in controlling their own medical data.

Twitter: @Bernie_HITN Email the writer: bernie.monegain@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Originally posted here:

Apple reveals plans to put health records on the iPhone - Healthcare IT News

Analyses of liver cancer reveals unexpected genetic players – Baylor College of Medicine News (press release)

Liver cancer has the second-highest worldwide cancer mortality, and yet there are limited therapeutic options to manage the disease. To learn more about the genetic causes of this cancer, and to identify potential new therapeutic targets for HCC, a nation-wide team of genomics researchers co-led by David Wheeler, Director of Cancer Genomics and Professor in the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine, and Lewis Roberts, Professor of Medicine at the Mayo Clinic, analyzed 363 liver cancer cases from all over the world gathering genome mutations, epigenetic alteration through DNA methylation, RNA expression and protein expression. The research appears in Cell.

Part of the larger Cancer Genome Atlas project (TCGA), this work represents the first large scale, multi-platform analysis of HCC looking at numerous dimensions of the tumor. There have been large-cohort studies in liver cancer in the past, but they have been limited mainly to one aspect of the tumor, genome mutation. By looking at a wide variety of the tumors molecular characteristics we get substantially deeper insights into the operation of the cancer cell at the molecular level, Wheeler said.

The research team made a number of interesting associations, including uncovering a major role of the sonic hedgehog pathway. Through a combination of p53 mutation, DNA methylation and viral integrations, this pathway becomes aberrantly activated. The sonic hedgehog pathway, the role of which had not been full appreciated in liver cancer previously, is activated in nearly half of the samples analyzed in this study.

We have a very active liver cancer community here at Baylor, so we had a great opportunity to work with them and benefit from their insights into liver cancer, Wheeler said. Among the many critical functions of the liver, hepatocytes expend a lot of energy in the production of albumin and urea. It was fascinating to realize how the liver cancer cell shuts these functions off, to its own purpose of tumor growth and cell division.

Intriguingly, we found that the urea cycle enzyme carbamyl phosphate synthase is downregulated by hypermethylation, while cytoplasmic carbamyl phosphate synthase II is upregulated, said Karl-Dimiter Bissig, Assistant Professor of Molecular and Cellular Biology at Baylor and co-author of the study. This might be explained by the anabolic needs of liver cancer, reprogramming glutamine pathways to favor pyrimidine production potentially facilitating DNA replication, which is beneficial to the cancer cell.

Albumin and apolipoprotein B are unexpected members on the list of genes mutated in liver cancer. Although neither has any obvious connection to cancer, both are at the top of the list of products that the liver secretes into the blood as part of its ordinary functions, explained Dr. David Moore, professor of molecular and cellular biology at Baylor. For the cancer cell, this secretion is a significant loss of raw materials, amino acids and lipids that could be used for growth. We proposed that mutation of these genes would give the cancer cells a growth advantage by preventing this expensive loss.

Multiple data platforms coupled with clinical data allowed the researchers to correlate the molecular findings with clinical attributes of the tumor, leading to insights into the roles of its molecules and genes to help design new therapies and identify prognostic implications that have the potential to influence HCC clinical management and survivorship.

This is outstanding research analyzing a cancer thats increasing in frequency, especially in Texas. Notably, the observation of gene expression signatures that forecast patient outcome, which we validate in external cohorts, is a remarkable achievement of the study. The results have the potential to mark a turning point in the treatment of this cancer, said Dr. Richard Gibbs, director of the HGSC at Baylor. The HGSC was also the DNA sequence production Center for the project.

Wheeler says they expect the data produced by this TCGA study to lead to new avenues for therapy in this difficult cancer for years to come. There are inhibitors currently under development for the sonic hedgehog pathway, and our results suggest that those inhibitors, if they pass into phase one clinical trials, could be applied in liver cancer patients, since the pathway is frequently activated in these patients, added Wheeler.

This work was supported by the National Institutes of Health and represents the last major cancer to be analyzed in the TCGA program. See a full list of contributors.

Read the original here:

Analyses of liver cancer reveals unexpected genetic players - Baylor College of Medicine News (press release)

ACMG’s Genetics in Medicine Journal Receives Record High Impact Factor of 8.229 for 2016: GIM Now in Top 2.5% of … – PR Newswire (press release)

"We are very excited that the Impact Factor has again increased for Genetics in Medicine. This is a testament to the excellent work by those in the genetics field who have been kind enough to submit their high-quality work to GIM, the hard work of the editorial board and the strength of the American College of Medical Genetics and Genomics. It is also an important reflection of the fact that genetics and genomics are increasingly important in the broader practice of medicine," said GIM's Editor-in-Chief Jim Evans, MD, PhD, FACMG. Evans added that the journal's success is a reflection of the importance, contributions and visibility of the American College of Medical Genetics and Genomics.

ACMG President Louanne Hudgins, MD, FACMG said, "Dr. Jim Evans and the entire editorial team at Genetics in Medicine should be congratulated on this great accomplishment! The steady rise of the impact factor for GIM over the past several years reflects the incredible hard work of Dr. Evans, the editorial board and the staff. It also highlights the critical role of medical genetics and genomics in the practice of medicine and the excellent science being performed by the authors, many of whom are members of the ACMG. This important publication is essential in promulgating ACMG's official policy statements and clinical and laboratory guidelines, thereby improving the practice of medical genetics."

Genetics in Medicine is published by Springer Nature (www.nature.com/gim).

The journal, published since 1998, is supported by an expert Board of Editors representing all facets of genetic and genomic medicine, including such specialties as biochemical genetics, cytogenetics and pharmacogenetics.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, ACMG is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics. The American College of Medical Genetics and Genomics (www.acmg.net) provides education, resources and a voice for more than 2000 biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. The College's mission is to develop and sustain genetic initiatives in clinical and laboratory practice, education and advocacy. Three guiding pillars underpin ACMG's work: 1) Clinical and Laboratory Practice: Establish the paradigm of genomic medicine by issuing statements and evidence-based or expert clinical and laboratory practice guidelines and through descriptions of best practices for the delivery of genomic medicine. 2) Education: Provide education and tools for medical geneticists, other health professionals and the public and grow the genetics workforce. 3) Advocacy: Work with policymakers and payers to support the responsible application of genomics in medical practice. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers a variety of resources including Policy Statements, Practice Guidelines, Educational Resources, and a Find a Geneticist tool. The educational and public health programs of the American College of Medical Genetics and Genomics are dependent upon charitable gifts from corporations, foundations, and individuals through the ACMG Foundation for Genetic and Genomic Medicine (www.acmgfoundation.org.)

Contact Kathy Ridgely Beal, MBA 301-238-4582 kbeal@acmg.net

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acmgs-genetics-in-medicine-journal-receives-record-high-impact-factor-of-8229-for-2016-gim-now-in-top-25-of-all-indexed-journals-300474733.html

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

See the original post here:

ACMG's Genetics in Medicine Journal Receives Record High Impact Factor of 8.229 for 2016: GIM Now in Top 2.5% of ... - PR Newswire (press release)

Newly revealed cellular pathway may lead to cancer therapies – Baylor College of Medicine News (press release)

Scientists have discovered a new cellular pathway that can promote and support the growth of cancer cells. In a mouse model of melanoma, blocking this pathway resulted in reduction of tumor growth. The study, which appears in Science, offers a novel opportunity to develop drugs that could potentially inhibit this pathway in human cancer cells and help control their growth.

We had been studying components of this pathway for several years, said senior author Dr. Andrea Ballabio, professor of molecular and human genetics at Baylor College of Medicine and Texas Childrens Hospital in Houston, Texas, and director of the Telethon Institute of Genetics and Medicine in Naples, Italy. We know that the pathway is important for normal cells to carry their activities as it is involved in regulating metabolism, that is, how cells process nutrients to obtain energy and how cells use energy to grow. In this study we wanted to learn more about how the pathway regulates its activity.

Pathways involved in cellular metabolism typically regulate themselves, meaning that some components of the pathway control each others activities. We suspected that the pathway was autoregulated, and we confirmed it in this study. Our experimental approaches showed that there is a feedback loop within the path that allows it to control itself.

An important pathway for normal cellular activities

Ballabio and his colleagues studied the role of the pathway in two normal cellular activities; how cells respond to physical exercise and how they respond to nutrient availability. In terms of physical exercise, the researchers determined that the self-regulating mechanism they discovered is essential for the body builder effect.

Some athletes take the aminoacid leucine or a mixture of aminoacids immediately after exercising, which promotes protein synthesis that leads to muscle growth. This is the body builder effect, Ballabio said. When we genetically engineered mice to lack the pathway, we lost the body builder effect.

The researchers had a group of normal mice and another of mice lacking the pathway. Both groups were set to exercise and fed leucine immediately after. While normal mice showed enhanced protein synthesis, the mice without the pathway did not.

In healthy organisms, this pathway also allows cells to adapt more efficiently to nutrient availability, Ballabio said. For example, when transitioning from a period of starvation to one in which food is available, cells need to switch from catabolism to anabolism. Starvation promotes catabolism the breakdown of nutrients to obtain energy to function and eating promotes anabolism the buildup of molecules, such as proteins. The feedback we discovered mediates the switch from catabolism to anabolism, allowing organisms to adapt to food availability.

An important pathway for cancer growth

The scientists also studied the role this pathway might play in cancer cells. They discovered that overactivation of this pathway, which is observed in some types of cancer such as renal cell carcinoma, melanoma and pancreatic cancer, is important to promote and support the growth of cancer cells in culture and animal models.

Most importantly, we demonstrated in our study that blocking the pathway resulted in reduction of tumor growth in an experimental model of human melanoma transplanted into mice, Ballabio said. I am most excited about the future potential therapeutic applications of this discovery against cancer. Developing pharmacological treatments that interfere with this pathway might one day help stop tumor growth.

Rare disease discoveries can improve our understanding of common diseases

Our lab focuses on rare genetic diseases, such as lysosomal storage genetic disorders, in which we originally studied this pathway, Ballabio said. Then, we discovered that the pathway is also important in cancer. Our and other researchers work on rare genetic diseases sometimes produces findings that can potentially be applicable to more common diseases, such as cancer.

For a complete list of the authors of this work and their affiliations, please refer to the published article.

This study was supported by grants from the Italian Telethon Foundation (TGM11CB6); European Research Council Advanced Investigator grant no. 250154 (CLEAR) and no. 341131 (InMec); U.S. National Institutes of Health (R01-NS078072); and the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) IG 2015 Id 17639 and IG 2015 Id 17717.

See the original post here:

Newly revealed cellular pathway may lead to cancer therapies - Baylor College of Medicine News (press release)

Alternative pricing models a fantasy for gene therapies? – BioPharma Dive

Once upon a time, gene therapy was thought to be the miracle of science that was going to change everything. After safety issues and patient deaths, that didnt work out quite like the industry had hoped.

Yet, 20 years later, the next generation of gene therapies is coming of age. These drugs so far have proven to be safer and more effective, but are raising new issues around cost. Many of the gene therapies being developed have the potential to be one-time treatments begging the question, how do you pay for something that could cure you after one dose?

This is the conundrum facing Spark Therapeutics, the West Philadelphia biotech poised to bring the first gene therapy to the U.S. market. Spark recently submitted an application to the Food and Drug Administration for voretigene neparvovec, a one-time gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal disease a rare genetic disorder that causes blindness. The company completed its rolling Biologics Licensing Application on May 18 and is awaiting confirmation from the FDA that it has been accepted. An approval could come by mid-2018 or earlier.

Spark CEO Jeff Marrazzo has said publicly that the company has been having conversations with payers and is prepared to take on the challenge of drug pricing.

"We founded Spark in 2013 and began thinking about it 2011. I spent five years working in government, working on matters of healthcare reform before there was the Affordable Care Act, so I have some perspective on at least from a government and policy perspective what people are thinking about. And with respect to Spark, none of our conversations about getting patients access began after someone increased a price, or someone tweeted about it or wrote an article about it. We were having these conversations long before any of that," said Marrazzo at the BIO CEO conference in New York on Feb. 14.

While the company has been thinking about pricing for some time, Spark has been mum about how it actually intends to the price voretigene neparvovec.

"With respect to gene therapy, I think it really has the potential to reframe what we are talking about, and [move the conversation toward] talking more about health than healthcare. What we talk about and pay for, specifically on a transactional basis, is healthcare, and more and more thats how we are reimbursed. I think what we need to move to is to paying more toward health," added Marrazzo.

"Were engaging in productive conversations with payers, both private and public, and are encouraged by the discussions so far. Were finding that theres broad agreement that the current payment system is not designed to reward the long-term value created by gene therapy," added Marrazzo in an email to BioPharma Dive.

Marrazzos hope that a new path with alternative pricing models can be created may be an overly optimistic one. U.S. payers have been slow to adopt new pricing models for other drug classes. Even outcomes-based pricing models are still few and far between.

"Gene therapies are single, one-time interventions with the potential to deliver sustained, life-altering benefits to patients, families and healthcare systems. At this early stage, we are exploring potential payment, distribution and reimbursement models where we might address budgetary concerns or be paid for performance to further align with the potential long-term benefits of our investigational therapies. Clearly, different gene therapies may call for different pricing models in different markets," said Marrazzo to BioPharma Dive.

Jeff Marrazzo at BIO CEO

Lisa LaMotta, Editor BioPharma Dive

If Europe is any indication, alternative pricing models for gene therapies are not on the horizon. The first gene therapy hit the EU market in 2012, brought to patients with an ultra-rare disease by small biotech UniQure. Glybera (alipogene tiparvovec) was priced at about $1 million for a treatment a single treatment like what Spark offers. Reportedly, it was only ever used on one patient and while that patient has been reportedly doing well, Glybera was a commercial failure. UniQure opted not to renew the drugs marketing authorization in the EU in April, finally abandoning all effort into the therapy.

The failed Glybera experiment makes it clear that one-time administration gene therapies cannot follow the typical rare disease-pricing model. For the last several years, rare disease drug makers have been able to price their therapies at a higher rate upwards of $300,000 annually in many cases due to the extremely small patient populations and the lack of other available treatments. While this isnt ideal, most patients dont pay the full cost due to rebates and discounts, and the small patient populations mean there is less burden on the healthcare system overall. This pricing model is increasingly coming into question as drug makers develop more and more rare disease treatments, and the costs continue to climb.

Alternative pricing models have been proposed for one-time, or extremely long-acting, therapies such as those currently being developed for hemophilia. While these models are purely theory at the moment and likely far from reality, there has been talk of putting patients on a payment plan, having them make payments on a one-time treatment like a mortgage. The model would rely on the premise that as long as a patient continues to be healthy, they pay towards the treatment (at least for a set number of years or once a certain price cap is reached).

Yet, Spark has backed away from making concrete comments on the topic. The company has eluded and analysts believe it will stick with a single high price tag as per the typical rare disease model.

"Part of whats important to understand, we can come up with all sorts of various alternatives, but we have [to propose] an alternative that the other party can accommodate and succeed with. We dont want to have an approval and then waste time trying to come up with the perfect payment model," said Marrazzo at BIO CEO.

Until the agency grants an approval, the public is unlikely to get more details on the price for voretigene neparvovec. In the meantime, Spark is prepping its launch. The company has started a patient and physician education plan, as well as a genetic testing initiative.

Through a program dubbed ID YOUR IRD, the company is providing free, simple and fast access to genotyping. In addition, the medical field team is working to locate previously identified inherited retinal disease (IRD) patients at leading eye institutions.

"We have invested in disease education and built strong relationships with the patient advocacy community, demonstrating Sparks commitment to improving patient care through new models of diagnosis, delivery and access," Marrazzo added."Weve proactively engaged with regulators throughout the development of investigational voretigene neparvovec. In parallel, weve had many conversations with payers and experts both in the United States and in Europe to characterize the burden of disease and consider carefully the value that investigational voretigene neparvovec may provide."

Even if commercialization preparation goes well, payers may push back. Other rare disease drugs that have reached the market lately have not gotten the warm reception that they expected.

For instance, Sarepta Therapeutics recently approved Duchenne muscular dystrophy drug Exondys 51 (eteplirsen) is not being received well by payers, despite a patient population of children that has advocated for the drug for years. Several major insurers have refused to cover the drug or only cover it on a limited basis that makes a $300,000 a year treatment very hard to afford.

For Spark and other gene therapy drugmakers that follow, there will be an uphill battle as they enter an environment rife with public criticism about drug pricing.

Read the original post:

Alternative pricing models a fantasy for gene therapies? - BioPharma Dive

Rachel Hatch, futurist and community vitality expert, to keynote regionalism / workforce track – The Gazette: Eastern Iowa Breaking News and Headlines

Iowa Ideas

Jun 15, 2017 at 4:26 pm

Rachel Hatch, program officer for community vitality at The McConnell Foundation, will keynote the regionalism / workforce track at Iowa Ideas 2017. Hatch will speak Thursday, September 21in Cedar Rapids.

Hatch will bring a unique perspective to Iowa Ideas as a Cedar Falls native who has spent nearly a decade in Northern California, working with some of the world's largest companies to study and act on emerging trends.

The McConnell Foundation, which is based out of California, focuses on building better communities through philanthropy and awards money to non-profits, public education agencies and government agencies in Northern California. Hatch is currently concentrating on downtown revitalization in the community of Redding, California.

She previously served as the research director at the Institute for the Future, a think tank based in Palo Alto, California. She worked with Fortune 100 companies, government groups and philanthropic organizations to focus on trends and disruptions that are likely to influence their work in the next decade.

The aim of foresight is to anticipate the future in order to make better decisions in the present, she said in a reflection about her time with the Institute for the Future.

Rachel is also co-curator of TEDxRedding, which brings together practical visionaries from the Redding area and beyond to share ideas.

The Iowa Ideas Conference, Sept. 20-22, will include 80 sessions and more than 250 speakers across eight tracks. The statewide gathering will mix panel discussions, interviews with state leaders and thought-provoking experiences to help move complex issues forward. Iowa Ideas is for anyone: doers, industry leaders, policy makers, lifelong learners and those who want to lead the conversation about the future of our state.

Other topics to be discussedin the Regionalism / Workforce track include new approaches to workforce development, the impacts of technology on Iowa's employers, the role of immigrants and diverse populations in Iowa's workforce, rural community vitality and regional efforts.

Iowa Ideas 2017 will kick off Wednesday, September 20, with an opening celebration and keynote address from best-selling author and innovation expert Alec Ross.

Go here to see the original:

Rachel Hatch, futurist and community vitality expert, to keynote regionalism / workforce track - The Gazette: Eastern Iowa Breaking News and Headlines

12th Annual IT CAME FROM…THE NEO-FUTURARIUM! Lineup Announced – Broadway World

Neo-Futurist alumnae Rachel Claff and Dina Walters curate It Came from ... the Neo-Futurarium XII: Dawn of the Neo-Futurarium! the 12th annual series of staged readings of the best worst film scripts of all time.

The summer 2017 festival features four of the clunkiest, junkiest movies ever made (details below), brought to life by past and present Neo-Futurists and acclaimed guest artists. Includes a Pride weekend show and gender-bending casts.

The festival will take place Saturdays at 7:30 p.m. (performances run 75-90 minutes without intermission):

Caged! (1950), June 24, 2017 Face/Off (1997), July 1, 2017 Suspiria (1977), July 8, 2017 Someone I Touched (1975), July 15, 2017

All events take place at The Neo-Futurarium, 5153 N. Ashland Ave., Chicago, IL 60640. Some street parking; Berwyn El stop (Red line); #92 (Foster) bus; #22 (Clark) bus.

Online tickets at neofilmfestxii.eventbrite.com. $15 for each performance; $12 for students (with ID); $50 for a festival pass (all four shows)

ABOUT THE FILMS:

June 24: Caged! (1950) - Nave teenager Marie is thrown into the ladies' slammer for being an accessory to robbery. Will she come out a woman ... or a wildcat? Bust out and come to this over-the-top Pride Weekend reading featuring an all-female-identified cast! Directed by Neo-Futurist alumnus David Kodeski (Wicked Woman; The Flaming Urge) and festival curator Rachel Claff.

July 1: Face/Off (1997) - In our 2009 reading of Cool as Ice, Dina Walters played the role she was born to play: Vanilla Ice. This year she plays the other role she was born to play: Nicolas Cage. Trying to take her down (via sketchy surgical science) is Neo-Futurist Kristie Koehler-Vuocolo as John Travolta. Bullets and doves will fly in this face-swappin', gender-swappin' spectacular! Walters also directs.

July 8: Suspiria (1977) - From the moment she arrives at the prestigious Tanz Academy, ballet dancer Suzy Bannion senses that something horribly evil lurks within its walls. So what if Suspiria's got gorgeous cinematography and buckets of gore? Director and Neo-Futurist alumna Stephanie Shaw is out to prove that this gonzo Italian horror film is as chock full of cheese as a good manicotti.

July 15: Someone I Touched (1975) - Man, made-for-TV movies were so different in the 1970s. Like, remember that one where a pregnant Cloris Leachman's husband cheated on her with a teenager and got syphilis? And then Cloris was worried her baby wouldn't have arms? But she still found time to sing the movie's theme song? *Sigh* Those were the days. Directed by festival veteran Edward Thomas-Herrera (Devil Girl from Mars; Sorority Girl).

Production team: Neo-Futurist alumna Rachel Claff (Creator, Head Curator), Neo-Futurist alumna Dina Walters (Assistant Curator), Jeremy Hornik (Selection Committee; Production), Jason Meyer (Selection Committee; Production), Bob Stockfish (Selection Committee; Production), and Neo-Futurist alumna MeLinda Evans (Technician).

It Came from ... the Neo-Futurarium! (staged readings of the best bad films of all time) was founded in 2002 by Neo-Futurist alumna Rachel Claff. Since then, over 60 terrible, awful movies have been staged, from sci-fi schlock (Devil Girl from Mars; Night of the Lepus) to deplorable drama (Day of the Dolphin) to miserable musicals (The Apple; Purple Rain) to appalling animation (My Little Pony: The Movie).

The festival has featured countless Neo-Futurists as well as theater companies from Chicago and beyond, including The House Theatre, The Plagiarists, Barrel of Monkeys, WildClaw Theatre, and Dad's Garage (Atlanta, GA). The "film fest," as it's affectionately called, has consistently played to sold-out crowds of movie aficionados and has garnered attention from the Chicago Tribune, Time Out Chicago, A/V Club, and more.

More information about ICFTNF is at http://www.facebook.com/ICFTNF, and for more about the Neo-Futurists, go to neofuturists.org or call 773-275-5255.

Read more:

12th Annual IT CAME FROM...THE NEO-FUTURARIUM! Lineup Announced - Broadway World

Astronomers Discover That Our Sun Likely Had an Evil Twin That Killed the Dinosaurs – Futurism

In Brief Scientists believe that most, if not all, sun-like stars are born with a twin. Evidence also suggests that our solar system's sun's twin may be responsible for knocking the comet that killed the dinosaurs toward Earth. Stellar Doppelganger

We have long known that the dinosaurs were killed by a catastrophic comet impact with the Earths surface but what if there was some foul play afoot? Astronomers have discovered that our sun may have been born with a twin, and an evil one, at that. One hypothesisstates that every 27 million years, the evil twin, aptly dubbed Nemesis, returns to wreck havoc on the solar system. They believe that the star lobs a few meteors in our direction as it makes its may through the outer limits of the solar system.

Research has lead scientists to believe that most stars are born with at least one sibling. According to UC Berkeley astronomer Steven Stahler, We ran a series of statistical models to see if we could account for the relative populations of young single stars and binaries of all separations in the Perseus molecular cloud, and the only model that could reproduce the data was one in which all stars form initially as wide binaries.

These findings could have implications for our understanding of how stars are formed. Looking into how they maintain or break those familial relationships will give us a deeper understanding of how our Universe came to be what it is today. Stahler said, Our work is a step forward in understanding both how binaries form and also the role that binaries play in early stellar evolution. Stahler also pointed out that this could even lead to a better understanding of how galaxies are formed.

These findings were made possible by the VLA nascent disk and multiplicity survey (VANDAM) which took a census of a group of baby stars merely a half-million years old. Their findings have been accepted for publication in the Monthly Notices of the Royal Astronomical Society and can be read pre-publication at arXiv.org.

See the rest here:

Astronomers Discover That Our Sun Likely Had an Evil Twin That Killed the Dinosaurs - Futurism

Elon Musk Puts a Cap on Ticket Price to Mars Colony. Here’s How Much It Could Cost. – Futurism

In Brief Elon Musk's talk at the International Astronautical Congress has been adapted as a journal article in this month's New Space. The CEO of SpaceX focuses on the affordability of tickets to Mars as a key factor in its successful colonization. Mars Planning

Elon Musk, CEO of SpaceX, delivered an address at the International Astronautical Congress held in Guadalajara, Mexico last year outlining his vision of getting humans into space. This talk has now been adapted into a fifteen-page article that was published in this months issue of the journal New Space. Musk focuses on affordability as a major factor to ensuring the possibility of Mars colonization. He says You cannot create a self-sustaining civilization if the ticket price is $10 billion per person. He believes that the cost should be about $200,000; equivalent to the median price of a house in the United States.

Musk outlines the steps he considers essential to ensuring this relative affordability. The first step, developing fully reusable transport, is already well underway at SpaceX. The company has already proven the reliability of itsreusable rockets,and have recently demonstratedthe reusability of theDragon spacecraft. Fueling is also a key factor in controlling costs: equipping any craft with additional fuel will significantly increase the weight of the craft. Musk proposes using methane which is produced on Mars and would thereforeallow for refueling viasources directly on the plant.

Many experts believe that in order to ensure the survival of our species, we must work to be multi-planetary beings. Perhaps Musks vision to get us to Mars is the first step toward that goal. Musks enthusiasm for his Mars project is quite timely if we are to believe Stephen Hawking, who predictshumanity only has 100 years left on Earth.

But colonizing Mars is only a one possibility space has to offer. Space miningand manufacturingcan help to decrease the burden on Earths resources and give us the capabilityto create products that would be impossible to manufacture on Earth.

We are at the beginning of an exciting crossroads for humanity. The space race of the mid-20th century brought about great change for humanity. Its looking like this iteration will completely transform us.

Read this article:

Elon Musk Puts a Cap on Ticket Price to Mars Colony. Here's How Much It Could Cost. - Futurism

A New Solar Paint Lets You Transform Your Entire House Into a Source of Clean Energy – Futurism

In Brief Researchers from the Royal Melbourne Institute of Technology have developed a paint that can generate hydrogen fuel from moist air and sunlight. The team expects the technology to be ready for commercial use in five years. Powerful Paint

Powering homes using clean energy is becoming easier thanks to a growing number of innovative technologies and initiatives. Some government programs help homeowners with the financial burden of equipping their residences with energy-generating solar panels, and Elon Musks Tesla has developed roofing tiles that double as solar panels to give solar power generation an aesthetic boost. Now, a new innovation out of Australia is poised to make clean energy even more appealing.

A team of researchers from theRoyal Melbourne Institute of Technology (RMIT) has developed a paint that can be used togenerate clean energy. The paint combines the titanium oxide already used in many wall paints with a new compound: synthetic molybdenum-sulphide. The latter acts a lot like the silica gel packaged with many consumer products to keep them free from damage by absorbing moisture.

According to a report on RMITs website, the material absorbssolar energy as well as moisture from the surrounding air. It can then split the water into hydrogen and oxygen, collecting the hydrogen for use in fuel cells or to power a vehicle. [T]he simple addition of the new material can convert a brick wall into energy harvesting and fuel production real estate, explained lead researcher Dr. Torben Daeneke.

Though the paint isnt expected to be commercially viable within the next five years, Daeneke told Inverse he believes the end product will be cheap to produce. He also claims the paint would be effective in a variety of climates, from damp environments to hot and dry ones near large bodies of water: Any place that has water vapor in the air, even remote areas far from water, can produce fuel.

The paint could be used to cover areas that wouldnt get enough sunlight to justify the placement of solar panels, maximizing the capability of any property to generate clean energy. Any surface that could be painted a fence, a shed, a doghouse could be transformed into an energy-producing structure.

When this new material finally makes its way to consumers, itll join the ever-growing list of innovative technologies that are moving humanity away from fossil fuels and toward a future of clean, renewable sources of energy.

See the rest here:

A New Solar Paint Lets You Transform Your Entire House Into a Source of Clean Energy - Futurism

Elon Musk: The Next Generation Tesla Roadster May Achieve 60 MPH in Under 2 Seconds – Futurism

In Brief CEO Elon Musk hinted at a possible target for the next generation of Tesla Roadsters expected to launch by 2019, and it's going to be the fastest one yet. Of course, with all the vehicles Tesla's currently working on, we'll have to wait a while to test it ourselves.

From 2008 and 2012, Tesla actually had a line of electric sports cars called the Tesla Roadster, which was the first-ever highway legal serial production of an all-electric car powered by lithium-ion batteries. Tesla has since discontinued its production, but it was announced three years ago that a second generation roadsteris coming.

CEO Elon Musk plans for this Tesla Roadster 4.0, so to speak, to outdo the first version. It will be capable of a Maximum Plaid performance mode, as Musk would call it in reference to the movie Spaceballs. In a recent tweet, Musk hinted at just how fast this Maximum Plaid would be.

If the first generation, had a Ludicrous mode capable of 0 to 97 km/h (60 mph) acceleration in just 2.5 seconds, the Tesla Roadster 4.0 might just hit 97 km/h (60 mph) in under two seconds. That would [be] an interesting target, Musk said in a tweet, replying to a question about the new roadster.

Would, of course, only count if capable of doing so right off the production line with street legal tires, Musk added, which Electreks Fred Lambert considers a possibility for the roadster to be faster with aftermarket components.

However, because Tesla is still busy with launching the Model 3 and perhaps working on the Model Y, and not to mention the highly-anticipated all-electric semi, the roadster is still a few years away supposedly in 2019. But the Roadster still gives Tesla fans who love sports cars something to look forward to.

Here is the original post:

Elon Musk: The Next Generation Tesla Roadster May Achieve 60 MPH in Under 2 Seconds - Futurism

Color-Changing Tattoos Could Help Millions Monitor Their Health in … – Futurism

In Brief A collaboration between MIT and Harvard has yielded a fascinating new way to monitor dynamic levels in blood using color-changing tattoo ink. Though the team has no plans to pursue clinical trials, the technology could foreshadow the future of blood level monitoring. The Tattoo Test

Researchers from Massachusetts Institute of Technology (MIT)and Harvard Medical School have developed a tattoo ink that could provide real-time updates on the bodys health. By making ink that responds to interstitial fluid the liquid in which our cells are suspended the researchers have found a unique way to monitor blood glucose, sodium, and ph levels.

The idea of the DermalAbyss project is that an individual would have the ink tattooed onto their body in the pattern of their preference. The tattoo would then change color according to the amount of the activating agent present. A tattoo using the ink designed to respond to glucose levels, for example, would change color from blue to brown as the persons blood sugar level rises.

The technology is an ingenious interaction of the body-art, medical, and bio-sensor sectors. While the researchers haveno immediate plans to release their inkto the public, the potential of the project is huge, and others could possibly explore and expand upon it in the future.

Aside from the initial tattooing process, the researchers skin interfaces are non-invasive, unlike the methods currently usedto monitor diabetes. Theyre also much harder to damage than current wearable technology.

That means the tech could improve millions of lives in the United States alone by helping the 10 percent of the population with diabetesmore easily monitor their disease.

As stated on the project website,the technology could potentially be used to measure far more than just the levels tested in the study: It could be used for applications in [continuous] monitoring, such as medical diagnostics, quantified self, and data encoding in the body.

This isnt the only research exploring innovative uses of tattoos others have found ways to link body ink to sound filesor use it to control smartphones but this research is the first to explicitly explore the medical possibilities of inked biosensors. Though just a proof of concept right now, DermalAbyss could be offering us a glimpse into the future ofhealth monitoring.

View original post here:

Color-Changing Tattoos Could Help Millions Monitor Their Health in ... - Futurism

Wings of Freedom tour visits Corvallis | KVAL – KVAL

World War II era aircraft are at the Corvallis Airport through noon Friday as part of the Wings of Freedom tour put on by the Collings Foundation. (Ray Whittemore Photography)

CORVALLIS, Ore. - World War II era aircraft are at the Corvallis Airport through noon Friday as part of the Wings of Freedom tour put on by the Collings Foundation.

Walk-through tours of the aircraft are available until 5 p.m. Thursday and from 9 to noon Friday.

Tickets are $15 for adults and $5 for children 12 and under.

Flights are available for a fee.

The tour moves on to Aurora, Oregon, on Friday. The planes will be available for tours and flights starting at 2 p.m. Friday and through 5 p.m. on Sunday.

After that the tour moves on to Bremerton, Wash., on June 19; Port Angeles, Wash., on June 21; and Seattle on June 23 before heading east to Yakima on June 26 and Pasco on June 30.

Flights are available before and after the ground tours.

The advertised rates are:

Call 978-562-9182 for flight reservations.

See the article here:

Wings of Freedom tour visits Corvallis | KVAL - KVAL

Route 65 in Freedom to close again this weekend – Timesonline.com

FREEDOM -- PennDOT has announced northbound Route 65 in Freedom will be closed Friday night through Monday morning, weather permitting.

The northbound lanes will close to traffic 6 p.m. Friday and reopen 6 a.m. Monday as crews conduct painting on the bridge that carries traffic from Third Avenue to southbound Route 65 in Freedom. All northbound traffic will be detoured.

As the posted detour, northbound traffic will take the Freedom exit and follow Third Avenue to the northbound Route 65 ramp.

Additionally, southbound Route 65 traffic will be restricted to a single 10-foot, 6-inch lane during the entire weekend. Third Avenue will also be restricted to 10-foot, 6-inch lanes.

Four additional weekend closures are necessary to complete the bridge-painting operation.

This $20.21 million roadway project includes milling and resurfacing, concrete pavement patching, drainage and guardrail updates, ramp reconstruction, curb and sidewalk work, bridge and retaining wall preservation, sign structure maintenance and signal improvements. The overall project will conclude in late October 2017.

Gulisek Construction Co. is the prime contractor.

Read the rest here:

Route 65 in Freedom to close again this weekend - Timesonline.com